Merriman Curhan Ford Downgrades Poniard Pharmaceuticals (PARD) to Neutral After Disappointing Phase III SPEAR Trial Results
Tweet Send to a Friend
Merriman Curhan Ford downgrades Poniard Pharmaceuticals (Nasdaq: PARD) from Buy to Neutral
Merriman analyst says, "Poniard reported disappointing results of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Merriman analyst says, "Poniard reported disappointing results of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
